uniQure N.V. (QURE)
| Market Cap | 3.59B |
| Revenue (ttm) | 14.34M |
| Net Income (ttm) | -199.00M |
| Shares Out | 68.10M |
| EPS (ttm) | -3.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,210,130 |
| Open | 50.43 |
| Previous Close | 47.50 |
| Day's Range | 46.56 - 54.98 |
| 52-Week Range | 4.45 - 54.98 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 65.08 (+23.61%) |
| Earnings Date | Nov 4, 2025 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]
Financial Performance
In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for QURE stock is "Strong Buy." The 12-month stock price target is $65.08, which is an increase of 23.61% from the latest price.
News
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease ge...
uniQure Stock Jumps On Positive News, But Risks Remain
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in t...
UniQure: How QURE Stock Rises 10x To $500?
UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II ...
Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it
A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease.
uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond
uniQure N.V. achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 study. Plan for a pre-BLA meeting with the FDA in H2 2025, targeti...
uniQure Announces $200 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
uniQure N.V. - Special Call
uniQure N.V. - Special Call Company Participants Chiara Russo Matthew Kapusta - CEO & Executive Director Dr. Walid Abi-Saab Kylie O'Keefe - Chief Customer & Strategy Officer Conference Call Participan...
QURE stock skyrockets 200% on ‘three' big news
Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday – marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a breakt...
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
uniQure N.V. QURE on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington's disease.
UniQure's brain disorder drug slows disease progression in trial
UniQure's experimental gene therapy significantly slowed the progression of a brain disorder in an early-to-mid stage study, it said on Wednesday.
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 millio...
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external co...
uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data
uniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash rese...
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Ab...
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure's AMT-130 Gene Therapy Warrants An Upgrade
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough T...
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache...
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director, Investor Relations Matt Kapusta - Chief Executive Officer Walid...
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related...
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phas...